Soleno Therapeutics Inc
6XC
Company Profile
Business description
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
Contact
100 Marine Parkway
Suite 400
Redwood CityCA94065
USAT: +1 650 213-8444
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
152
Stocks News & Analysis
stocks
Chart of the Week: Inflation fears dampen sentiment on retailers
Rising inflation is the fly in the ointment.
stocks
Here’s 3 Top Rated ASX shares for 2026
As we start the new year, let’s take a closer look at three compelling opportunities on the ASX
stocks
Undervalued Aussie e-commerce winner
Shares attractive due to near term profit margin increase and structural growth.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,022.50 | 1.70 | -0.02% |
| CAC 40 | 8,233.92 | 3.51 | -0.04% |
| DAX 40 | 25,122.26 | 230.06 | 0.92% |
| Dow JONES (US) | 48,996.08 | 466.00 | -0.94% |
| FTSE 100 | 10,048.21 | 74.52 | -0.74% |
| HKSE | 26,228.91 | 230.04 | -0.87% |
| NASDAQ | 23,584.28 | 37.10 | 0.16% |
| Nikkei 225 | 51,622.48 | 339.50 | -0.65% |
| NZX 50 Index | 13,694.77 | 20.25 | -0.15% |
| S&P 500 | 6,920.93 | 23.89 | -0.34% |
| S&P/ASX 200 | 8,697.80 | 4.80 | -0.06% |
| SSE Composite Index | 4,082.43 | 3.34 | -0.08% |